NO762960L - - Google Patents
Info
- Publication number
- NO762960L NO762960L NO762960A NO762960A NO762960L NO 762960 L NO762960 L NO 762960L NO 762960 A NO762960 A NO 762960A NO 762960 A NO762960 A NO 762960A NO 762960 L NO762960 L NO 762960L
- Authority
- NO
- Norway
- Prior art keywords
- trans
- acid
- formula
- methylene
- group
- Prior art date
Links
- 239000002253 acid Substances 0.000 claims description 81
- 150000001875 compounds Chemical class 0.000 claims description 32
- 125000004432 carbon atom Chemical group C* 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 239000001257 hydrogen Substances 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 125000006239 protecting group Chemical group 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 7
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 239000004305 biphenyl Substances 0.000 claims description 3
- 235000010290 biphenyl Nutrition 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- -1 1-heptyl Chemical group 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 150000004702 methyl esters Chemical class 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 230000000572 bronchospasmolytic effect Effects 0.000 description 3
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003180 prostaglandins Chemical group 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 230000017105 transposition Effects 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000002997 prostaglandinlike Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- OEBIHOVSAMBXIB-SJKOYZFVSA-N selitrectinib Chemical compound C[C@@H]1CCC2=NC=C(F)C=C2[C@H]2CCCN2C2=NC3=C(C=NN3C=C2)C(=O)N1 OEBIHOVSAMBXIB-SJKOYZFVSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical class C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003191 uterotonic effect Effects 0.000 description 1
- 229940030508 uterotonics Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1159375 | 1975-09-05 | ||
| CH1628175 | 1975-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO762960L true NO762960L (da) | 1977-03-08 |
Family
ID=25708612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO762960A NO762960L (da) | 1975-09-05 | 1976-08-27 |
Country Status (14)
| Country | Link |
|---|---|
| JP (1) | JPS5233656A (da) |
| AU (1) | AU1749676A (da) |
| DE (1) | DE2638401A1 (da) |
| DK (1) | DK391076A (da) |
| ES (1) | ES451202A1 (da) |
| FI (1) | FI762467A (da) |
| FR (1) | FR2322594A1 (da) |
| GB (1) | GB1554925A (da) |
| IL (1) | IL50408A0 (da) |
| NL (1) | NL7609710A (da) |
| NO (1) | NO762960L (da) |
| NZ (1) | NZ181935A (da) |
| PT (1) | PT65553B (da) |
| SE (1) | SE7609505L (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08880B2 (ja) * | 1984-12-12 | 1996-01-10 | 住友ダウ株式会社 | 耐薬品性に優れる樹脂組成物 |
| JPH0757836B2 (ja) * | 1984-12-14 | 1995-06-21 | 住友ダウ株式会社 | 樹脂組成物 |
| JP2003064231A (ja) * | 2001-08-29 | 2003-03-05 | Asahi Kasei Corp | 耐候・耐衝撃性スチレン系樹脂組成物 |
| US6720386B2 (en) | 2002-02-28 | 2004-04-13 | General Electric Company | Weatherable styrenic blends with improved translucency |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO742378L (da) * | 1973-07-09 | 1975-02-03 | Sandoz Ag |
-
1976
- 1976-08-26 DE DE19762638401 patent/DE2638401A1/de not_active Withdrawn
- 1976-08-27 SE SE7609505A patent/SE7609505L/xx unknown
- 1976-08-27 NO NO762960A patent/NO762960L/no unknown
- 1976-08-27 FI FI762467A patent/FI762467A/fi not_active Application Discontinuation
- 1976-08-27 DK DK391076A patent/DK391076A/da unknown
- 1976-09-01 NL NL7609710A patent/NL7609710A/xx not_active Application Discontinuation
- 1976-09-02 GB GB36369/76A patent/GB1554925A/en not_active Expired
- 1976-09-03 IL IL50408A patent/IL50408A0/xx unknown
- 1976-09-03 NZ NZ181935A patent/NZ181935A/xx unknown
- 1976-09-03 ES ES451202A patent/ES451202A1/es not_active Expired
- 1976-09-03 PT PT65553A patent/PT65553B/pt unknown
- 1976-09-04 JP JP51105447A patent/JPS5233656A/ja active Pending
- 1976-09-06 AU AU17496/76A patent/AU1749676A/en not_active Expired
- 1976-09-06 FR FR7626743A patent/FR2322594A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| ES451202A0 (es) | 1977-11-16 |
| NZ181935A (en) | 1978-09-20 |
| DK391076A (da) | 1977-03-06 |
| PT65553B (fr) | 1978-10-10 |
| JPS5233656A (en) | 1977-03-14 |
| FR2322594B1 (da) | 1979-09-07 |
| FR2322594A1 (fr) | 1977-04-01 |
| ES451202A1 (es) | 1977-11-16 |
| IL50408A0 (en) | 1976-11-30 |
| GB1554925A (en) | 1979-10-31 |
| NL7609710A (nl) | 1977-03-08 |
| FI762467A (da) | 1977-03-06 |
| PT65553A (fr) | 1976-10-01 |
| AU1749676A (en) | 1978-03-16 |
| DE2638401A1 (de) | 1977-03-17 |
| SE7609505L (sv) | 1977-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0850926B1 (en) | Difluoroprostaglandin derivatives and their use | |
| IE53907B1 (en) | 9-fluoro-prostaglandin derivatives process for their manufacture and their use as medicaments | |
| NO20151341A1 (no) | Prostaglandinnitrooksyderivater | |
| IE51212B1 (en) | 9-chloroprostaglandin derivatives,process for the preparation thereof,and use thereof as medicinal agents | |
| US5004752A (en) | Novel 9-haloprostaglandins, processes for their preparation, and their use as medicinal agents | |
| US4004020A (en) | Novel prostanoic acid derivatives and process for the preparation thereof | |
| NO762960L (da) | ||
| CH619691A5 (da) | ||
| RU2073668C1 (ru) | СПОСОБ ПОЛУЧЕНИЯ 13,14-ДИГИДРО-17-ФЕНИЛЬНОГО АНАЛОГА PGF2α ИЛИ ПГЕ*002 | |
| CA1092102A (en) | 11-oxo-prostaglandin derivatives and processes for their manufacture | |
| NO143741B (no) | Analogifremgangsmaate for fremstilling av fysiologisk aktive prostaglandinforbindelser av e- og f-serien | |
| US4088775A (en) | 15-Ethylenedioxy-prostanoic acid derivatives and esters thereof and intermediates thereof | |
| NO142712B (no) | Analogifremgangsmaater for fremstilling av farmakologisk virksomme 9-desoksy-prosta-5,9,(10),13-tripelargonsyrederivater | |
| NO156524B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive carbacyclinderivater. | |
| JPS584763A (ja) | Δ８，９―プロスタグランジン誘導体及びその製法 | |
| KR100224951B1 (ko) | 15-데옥시프로스타글란딘유도체 | |
| NO146280B (no) | Bis-tetrahydropyranyleter for anvendelse som mellomprodukt for fremstilling av en fysiologisk aktiv p-bifenylester av en prostaglandinanalog av e- eller f-serien | |
| CA1041012A (en) | Method of reducing the incidence of gastrointestinal side effects during the treatment of inflammatory conditions with antiinflammotory drugs and compositions therefor | |
| NO151363B (no) | Analogifremgangsmaate for fremstilling av terapeutisk virksomme 16-metoksy-16-metyl-prostaglandin e1-derivater | |
| EP0010360A1 (en) | Prostane derivatives, processes for their preparation and their pharmaceutical compositions | |
| NO169791B (no) | Neddykket hydraulisk enhet for styring av en undersjoeisk-oljearbeidsstasjon | |
| CA1186306A (en) | Optically active 16-methoxy-16-methyl-prostaglandin e derivatives and a process for preparing them | |
| GB1589526A (en) | Prostaglandins and process for their manufacture | |
| CH626338A5 (en) | Process for the preparation of prostaglandin analogues | |
| IE43453B1 (en) | New 15-(1,3-benzodioxan-2-yl)-16,17,18,19,20-pentanor prostanoic acid derivatives and process for their manufacture |